Loading...
Loading...
- CytoSorbents Corporation CTSO reported Q2 revenue of $12 million, up 23% Y/Y, but missing the consensus of $12.27 million.
- Product sales increased 19% Y/Y to $11.4 million. Core non-COVID-19 product sales were a record $9.7 million, up 38% Y/Y.
- The Company estimates that COVID-19 related sales were approximately $1.7 million.
- Overall gross margin improved from 66.8% to 77.5%, though reported a wider operating loss of $(4.9) million, versus a loss of $(3.3) million a year ago.
- It posted a wider net loss of $(0.11) per share, up from $(0.08) a year ago and missing the consensus of $(0.04).
- R&D expenses witnessed a 54% Y/Y growth to $3.7 million due to pre-enrollment activities related to the STAR-T trial in the U.S.
- The FDA signed off the 120-patient trial in July.
- SG&A expenses expanded 49% Y/Y to $9.8 million.
- CytoSorbents maintains a cash balance of $65.6 million.
- Outlook: For the rest of 2021, the Company expects at least 30% Y/Y growth in the core, non-COVID-19 product sales.
- Overall, it expects second-half 2021 product sales to exceed the first half 2021 product sales.
- Also, on the conservative side, CTOS forecasts product sales associated with COVID-19 treatments to be less than $1 million in the second half of 2021, compared to approximately $3.5 million in the first half of 2021.
- Price Action: CTSO shares closed at $7.26 on Tuesday.
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in